ASCO 2022 preview webinar: Key trials with high clinical and commercial impact
Join us for a preview ASCO webinar where a panel of experts will share their perspectives on the potentially practice-changing results in breast cancer, novel approaches in Non-Hodgkin Lymphoma and Myelofibrosis, and a series of exciting MOAs in early-stage trials.
Speakers
Tags
Related Content
Newsletter
Oncology Newsletter │ May 2022
Key Trials with High Clinical and Commercial Impact at ASCO 2022 and more
Webinar
ASCO 2022 preview webinar: Key trials with high clinical and commercial impact
Join us for a preview ASCO webinar where a panel of experts will share their perspectives on the potentially practice-changing results in breast cancer, novel approaches in Non-Hodgkin Lymphoma and Myelofibrosis, and a series of exciting MOAs in early-stage trials.
Newsletter
Oncology Newsletter February 2022
Precision medicine the next generation and more
Newsletter
Oncology Newsletter │ June 2022
Highlights of ASCO 2022 and more
Newsletter
Oncology Newsletter │ April 2022
ASCO Preview 2022
Webinar
Immunotherapies are the scientific answer to cancer, how important is marketing?
In this webinar, experts from Cerner Enviza and life science industry will debate the evolving importance marketing and science are playing in the treatment of oncology patients.
Infographic
Evolution of the immune checkpoint inhibitor market landscape in China
Recent regulatory developments and increasing domestic competition in China are now shaping development strategy for global companies
Newsletter
Oncology Newsletter │ July 2022
Immune checkpoint inhibitors - market landscape in China and more
Infographic
Evolution of biomarker trials across the tumor spectrum
Biomarker driven clinical trials have quickly built momentum in oncology. Explore and understand two decades of developmental trends across a variety of tumors.
Newsletter
Oncology Newsletter January 2022
The evolution of biomarker driven clinical development and more
Infographic
The Breadth of PD(L)1 Development in 2021
Development of immuno-oncology drugs has risen dramatically. With 6 PD(L)1 agents now FDA approved, development now extends to multiple tumor types.
Infographic
Pearls of wisdom: Rare Cancer
Investigate how incidence of rare cancers varies across the U.S, EU, Japan and China.
Infographic
Navigating multiple myeloma
A more positive journey for patients with increased survival rates. View the some of the contributing factors over 2004 to 2014.
Infographic
The Oncology Race in Biotech
Many biotechs are looking for their first approval, including those with large clinical programs in the US and EU and ongoing Phase III trials.
White Paper
How to win in the evolving early-stage NSCLC landscape
Strategic considerations to successfully adapt to the rapidly changing NSCLC global market following the introduction of checkpoint inhibitors in resectable disease (non-driver)
Newsletter
Oncology Newsletter March 2022
The oncology race in biotech
White Paper
Immunotherapies are the scientific answer to cancer, but how important is marketing?
This white paper considers the key issues in oncology of: the rise of immuno-oncology brands, what is happening in the mind of the Oncologists, changing paradigm within Oncology and what does this mean for pharma?
Infographic
Precision Medicine: The Next Generation
For too long oncology patients have been treated with a one-size-fits-all treatment plan. The time has come for a more personalized approach.
Infographic
A Periodic Table of Biomarkers
Tumor-agnostic development strategies are gaining momentum as a way to treat solid and hematological tumors characterized by novel and existing biomarkers.
Infographic
The burden of cancer caregiving across the globe
Data from the National Health & Wellness Survey suggests population aging and economic development influence the role of cancer caregivers and the degree of health, productivity, and financial impacts they report.
Newsletter
Oncology Newsletter │ September 2022
Rare Cancer Day and more
Infographic
Better testing, better outcomes in Rare Cancer: BRCA mutation and PARP inhibitors
Could increased testing improve outcomes of more patients in rare cancer? And with HRR mutations occurring in multiple tumor types, are there more cancers these drugs can treat?
Infographic
For the record: CAR-T therapy
An overview of CAR-T trials by clinical phase of development for hematological and solid tumors
Infographic
Better testing, better outcomes in Rare Cancer: NTRK fusions
The diverse nature of NTRK fusions present challenges for identification and diagnosis given their rarity and heterogenous patient populations.
Infographic
Hitting the right targets: An overview of current ADC trials
ADCs target tumor cells with toxic chemotherapy payloads. This interactive infographic detailing the extent of pivotal trial activity by developer, tumor type, molecular target, and payload chemotherapy class
Newsletter
Oncology Newsletter │ August 2022
The value of Real-World Evidence in improving rare cancer care and more
Infographic
CAR-T and the growth of cell therapy trials
While CAR-T therapies are the dominant approach globally with development focused in the US and China, other therapy approaches are steadily rising.
Newsletter
Oncology Newsletter │ October 2022
CAR-T therapies have revolutionized cancer care and more
Newsletter
Oncology Newsletter │November 2022
Winning in the early-stage NSCLC immunotherapy landscape and more
Infographic
Head and neck cancer: Unique challenges require a holistic view
Unique challenges face H&N cancer patients, which gives rise to important considerations driving treatments decisions
Infographic
Signposting a path to better treatments
Trends in historical approvals and setbacks across different stages of disease in Esophageal, Pancreatic, Gastric, Hepatocellular, and Colorectal Cancers
Blog
“I kinda feel like a phony”: the emotional complexities of coping with cancer
In this blog, Cerner Enviza’s Search and Social Intelligence team share the online analysis results of diagnosed cancer patients, uncovering their hopes, fears and feelings.